Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (Nasdaq: FULC) announced a proposed underwritten public offering of $150.0 million of common stock with a 30-day underwriter option to purchase up to an additional $22.5 million of shares. All shares are to be sold by the company under an effective shelf registration previously filed with the SEC. Book-running managers include J.P. Morgan, Leerink Partners, and Cantor, with Oppenheimer and Truist also participating.

Fulcrum intends to use net proceeds for general corporate purposes, including R&D, clinical trials, regulatory submissions, commercialization, capital expenditures, and potential acquisitions. The offering is subject to market and other conditions; final terms will appear in a prospectus supplement filed with the SEC.

Fulcrum Therapeutics (Nasdaq: FULC) reported positive initial results from the 20 mg cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on Dec 6, 2025. At Week 6 (n=12) mean absolute fetal hemoglobin (HbF) rose from 7.1% to 16.9% (+9.9%), with 7 of 12 patients (58%) reaching ≥20% HbF. Among six patients reaching Week 12, mean fold induction exceeded 3.75x versus 2.4x in the 12 mg cohort. Markers of hemolysis and anemia improved (LDH -37%, indirect bilirubin -37%, reticulocytes -33%), mean hemoglobin +0.8 g/dL, and no treatment-related serious adverse events were reported.

Fulcrum Therapeutics (Nasdaq: FULC) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) for one newly hired employee on an effective date of December 1, 2025. The company granted 5,250 non-statutory stock options at an exercise price of $9.87 per share (the closing price on the grant date).

The options carry a 10-year term and vest over four years: 25% on the first anniversary of the employee’s start date, then 6.25% each quarter for the following 12 quarters, subject to continued service. The award was made pursuant to the company’s 2022 Inducement Stock Incentive Plan.

Fulcrum Therapeutics (Nasdaq: FULC) will host an investor event on December 7, 2025 at 7:00 a.m. ET to review new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD).

The presentation will include initial clinical data from the 20 mg dose cohort and full data from the 12 mg dose cohort, followed by a live Q&A. The same data will be presented at the 67th ASH Annual Meeting. A replay will be available on the company website and registration is available via the Events and Presentations page.

Fulcrum Therapeutics (Nasdaq: FULC) announced inducement equity grants for new hires under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted an aggregate of 270,000 non-statutory stock options to two employees and a 50,000 performance-based option to a third employee, each with an exercise price of $9.02 per share (closing price on the grant effective date, Nov 3, 2025).

The 270,000 options carry a 10-year term and vest over four years (25% after one year, then 6.25% quarterly over 12 quarters). The 50,000 performance option vests after 12 months subject to continued eligibility and achievement of predefined performance objectives, and will be forfeited if objectives are not met within six months of the grant date.

Fulcrum Therapeutics (Nasdaq: FULC) will present new clinical and preclinical data at the 67th American Society of Hematology Annual Meeting on December 6–7, 2025.

Pociredir Phase 1b PIONEER results will include full data from the 12 mg cohort and initial data from the 20 mg cohort in adults with severe sickle cell disease and hydroxyurea intolerance/unresponsiveness. A poster (ID 1157) is scheduled for Dec 6 and was selected for a Poster Walk on Dec 7. Fulcrum will host a live and webcast investor event on Dec 7, 2025 at 7:00 a.m. ET.

Fulcrum Therapeutics (NASDAQ: FULC) reported Q3 2025 results and clinical updates on Oct 29, 2025. Key clinical news: encouraging Phase 1b PIONEER 12 mg cohort results showing dose-dependent fetal hemoglobin (HbF) increases, hemolysis marker improvements, total hemoglobin gains, VOC reduction trends, and no drug-related SAEs through 12 mg. Enrollment completed in the 20 mg cohort (n=12); data expected by year-end 2025. Financials: $200.6M cash and marketable securities as of Sept 30, 2025, with a cash runway into 2028. Q3 R&D $14.3M, G&A $7.6M, net loss $19.6M.

Fulcrum Therapeutics (NASDAQ: FULC) will release its third quarter 2025 financial results on Wednesday, October 29, 2025, before U.S. markets open.

Management will host a conference call and webcast on October 29, 2025 at 8:00 a.m. ET to discuss results and provide a corporate update. Participants must register to receive dial-in details and a unique PIN. An audio webcast will be available on the company’s Investor Relations website and an archived replay will be posted after the live webcast.

Fulcrum Therapeutics (Nasdaq: FULC) will present preclinical data for FTX-6274, an oral EED inhibitor, showing potential activity in castration‑resistant prostate cancer (CRPC).

The poster (ID 2504P) led by Suchi Raghunathan will be shown at ESMO Congress 2025 in Berlin on Oct 18, 2025, 12:00–12:45 PM CEST. Fulcrum noted the data highlight EED inhibition beyond its hematology programs and said a strategic partnership could best advance oncology development. The poster will be posted on Fulcrum’s Publications & Presentations page after congress publication.